In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis. The data revealed 60% of trial patients experienced a significant improvement in
Read More
CF33-hNIS-antiPDL1. *moves mouse to x button to close tab* “But wait!” your writer screams from the page, “I promise it’s interesting!” Whilst I may not have the teaching prowess of Ms Frizzle, I implore you to stick around, because Imugene’s (ASX: IMU) immuno-oncology stuff is really interesting once you wrap your head around it. The
Read More
Prostate cancer patients could soon be in for potentially good news after clinical stage-drug development company, Noxopharm (ASX: NOX) reported interim data indicating effective anti-cancer responses from patients receiving treatment for late-stage prostate cancer. To date, the data from the study (DARRT-1) found that 80% of patients showed no further progression in their disease after
Read More